Evidence map›Paper›PMID 27421645›Full record

ArticleThe Journal of general virology2016

A novel phosphoserine motif in the LCMV matrix protein Z regulates the release of infectious virus and defective interfering particles.

Christopher M Ziegler, Philip Eisenhauer, Emily A Bruce, Vedran Beganovic, Benjamin R King, Marion E Weir, Bryan A Ballif, Jason Botten

Abstract read
In one paragraph

Article in The Journal of general virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christopher M ZieglerDepartment of Medicine, Division of Immunobiology, University of Vermont, Burlington, VT 05405, USA.
Philip EisenhauerDepartment of Medicine, Division of Immunobiology, University of Vermont, Burlington, VT 05405, USA.
Emily A BruceDepartment of Medicine, Division of Immunobiology, University of Vermont, Burlington, VT 05405, USA.
Vedran BeganovicDepartment of Medicine, Division of Immunobiology, University of Vermont, Burlington, VT 05405, USA.
Benjamin R KingDepartment of Medicine, Division of Immunobiology, University of Vermont, Burlington, VT 05405, USA.
Marion E WeirDepartment of Biology, University of Vermont, Burlington, VT 05405, USA.
Bryan A BallifDepartment of Biology, University of Vermont, Burlington, VT 05405, USA.
Jason BottenDepartment of Microbiology and Molecular Genetics, University of Vermont, Burlington, VT 05405, USA.

Funding

Vaccines and Diagnostics TrialsU54AI065359 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BARBOUR, ALAN G. · 2005 to 2013
$88.8M
Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CHRISTOPHER S FRANCKLYN · 2012 to 2026
$58.4M
VERMONT IMMUNOBIOLOIGY/ INFECTIOUS DISEASES CENTERP20RR021905 · NCRR · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HILL, JACK · 2006 to 2011
$14.5M
Vermont Immunology/Infectious Diseases CenterP30GM118228 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BUDD, RALPH C · 2016 to 2021
$6.8M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Vermont Immunology/Infectious Diseases Training GrantT32AI055402 · NIAID · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI GARY E WARD · 2005 to 2026
$2.7M
Identification of Novel Arenavirus Protein-Host Cellular Protein InteractionsR21AI088059 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BOTTEN, JASON W. · 2010 to 2011
$416k
NCRR NIH HHS P20 RR021905NHLBI NIH HHS T32 HL076122NIAID NIH HHS R21 AI088059NIAID NIH HHS T32 AI055402NIAID NIH HHS U54 AI065359NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P30 GM118228
6 · The paper itself

Abstract

We report that the lymphocytic choriomeningitis virus (LCMV) matrix protein, which drives viral budding, is phosphorylated at serine 41 (S41). A recombinant (r)LCMV bearing a phosphomimetic mutation (S41D) was impaired in infectious and defective interfering (DI) particle release, while a non-phosphorylatable mutant (S41A) was not. The S41D mutant was disproportionately impaired in its ability to release DI particles relative to infectious particles. Thus, DI particle production by LCMV may be dynamically regulated via phosphorylation of S41.

Indexed as

Amino Acid MotifsAmino Acid SubstitutionDefective VirusesLymphocytic choriomeningitis virusMutant ProteinsPhosphoserineViral Matrix ProteinsVirionMutant ProteinsPhosphoserineViral Matrix Proteins

Identifiers

PMID27421645
PMCPMC5756487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.